With this trend continuing it is expected that FY18 half year revenue will be in excess of $30 million.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential